Skip to main content

Table 3 Drug exposure and duration of illness

From: Persistent treatment with cholinesterase inhibitors and/or memantine slows clinical progression of Alzheimer disease

 

Treatment initiated

Duration of symptoms at the NPV

Before NPV

1-2 years after NPV

3 years after NPV

Never treated

Total

<2 years

37 (5.8)

49 (7.6)

5 (0.8)

18 (2.8)

109 (17.0)

2-3 years

98 (15.3)

112 (17.5)

10 (1.6)

33 (5.1)

253 (39.5)

4-5 years

79 (12.3)

80 (12.5)

2 (0.3)

13 (2.0)

174 (27.1)

≥6 years

59 (9.2)

34 (5.3)

1 (0.2)

11 (1.7)

105 (16.4)

Total

273 (42.6)

275 (42.9)

18 (2.8)

75 (11.7)

641 (100.0)

  1. Values are presented as number (percentage). NPV, new patient visit.